Revvity Inc. (NYSE:RVTY) Stock Has Consensus Target Price of $124.43

Key Points

• Analyst sentiment is mostly neutral: Eighteen analysts give Revvity an average “Hold” rating, with 13 holds and five buys. The consensus 12-month price target is $124.43, below the stock’s reported opening price of $160.43.
• Recent results exceeded expectations: Revvity reported quarterly EPS of $1.41 versus the $1.21 consensus estimate, while revenue reached $729.69 million. However, revenue declined 1.3% year over year, and analysts project full-year EPS of approximately $5.36.
• Investors receive a modest dividend, while insiders have been selling: The company declared a quarterly dividend of $0.07, equivalent to a 0.2% annual yield. Insiders sold 9,045 shares worth about $1.28 million over the past 90 days.

Shares of Revvity Inc. (NYSE:RVTY - Get Free Report) have been assigned an average rating of "Hold" from the eighteen ratings firms that are covering the stock, MarketBeat.com reports. Thirteen investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $124.43.

A number of equities analysts recently weighed in on RVTY shares. Weiss Ratings upgraded shares of Revvity from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 8th. UBS Group assumed coverage on shares of Revvity in a research report on Wednesday, September 9th. They set a "neutral" rating and a $140.00 price objective for the company. TD Cowen raised their target price on shares of Revvity from $130.00 to $175.00 and gave the stock a "buy" rating in a research note on Tuesday, October 13th. William Blair assumed coverage on shares of Revvity in a report on Monday, October 5th. They issued an "outperform" rating on the stock. Finally, Royal Bank Of Canada initiated coverage on shares of Revvity in a report on Tuesday, September 1st. They issued a "sector perform" rating and a $135.00 target price on the stock.

Revvity Stock Performance

Shares of Revvity stock opened at $160.43 on Tuesday. The firm's fifty day simple moving average is $140.14 and its 200-day simple moving average is $110.69. The stock has a market capitalization of $17.90 billion, a price-to-earnings ratio of 76.39, a PEG ratio of 2.89 and a beta of 1.06. Revvity has a 12 month low of $81.22 and a 12 month high of $166.25. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50.

Revvity (NYSE:RVTY - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts' consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million during the quarter, compared to analysts' expectations of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business's revenue was down 1.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts forecast that Revvity will post 5.36 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. The ex-dividend date is Friday, October 23rd. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. Revvity's payout ratio is 13.33%.

Insiders Place Their Bets

In other news, insider Maxwell Krakowiak sold 1,631 shares of the firm's stock in a transaction on Monday, September 21st. The stock was sold at an average price of $144.53, for a total value of $235,728.43. Following the completion of the transaction, the insider owned 14,781 shares in the company, valued at $2,136,297.93. This trade represents a 9.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Tajinder S. Vohra sold 7,330 shares of the stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $140.88, for a total value of $1,032,650.40. Following the sale, the insider owned 6,635 shares in the company, valued at approximately $934,738.80. This trade represents a 52.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,045 shares of company stock worth $1,281,439 in the last ninety days. 0.85% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Revvity

A number of large investors have recently bought and sold shares of the stock. Pillar Financial Advisors LLC purchased a new position in shares of Revvity in the 3rd quarter valued at $29,000. Ascentis Independent Advisors purchased a new stake in shares of Revvity in the first quarter worth about $29,000. Root Financial Partners LLC purchased a new stake in shares of Revvity in the third quarter worth about $64,000. Global Retirement Partners LLC acquired a new stake in shares of Revvity in the second quarter valued at about $51,000. Finally, SJS Investment Consulting Inc. grew its stake in shares of Revvity by 5,210.0% in the first quarter. SJS Investment Consulting Inc. now owns 531 shares of the company's stock valued at $47,000 after buying an additional 521 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company's stock.

About Revvity

Revvity, Inc provides technology, products and services for the life sciences and diagnostics markets. The company supports pharmaceutical and biotechnology research, clinical laboratories and other healthcare organizations with tools used in drug discovery, biological research, disease detection and laboratory testing.

Its offerings include laboratory instruments, reagents, consumables, software and workflow solutions. Key areas include genomics, proteomics, cellular analysis, imaging, screening, automation and reproductive health, as well as newborn screening and other diagnostic applications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.